**Eli Lilly’s Kisunla Alzheimer’s Drug Fails to Secure EU Approval**
Eli Lilly & Co.’s Alzheimer’s drug, Kisunla, has not received the endorsement of European regulators due to concerns that its benefits do not outweigh the risks of potentially fatal brain bleeding. The European Medicines Agency’s (EMA) drug advisory committee made this recommendation on Friday, which is now awaiting a final decision from the European Commission. Lilly expressed disappointment and plans to pursue another review, emphasizing its confidence in the drug’s safety and efficacy.
### Setback for Eli Lilly in Alzheimer’s Treatment Market
– **Competition**: Lilly is in a competitive race with Eisai Co. and Biogen Inc. in the global Alzheimer’s treatment market, which is projected to grow from approximately $250 million last year to $13 billion by 2030, according to Bloomberg Intelligence.
– **Safety Concerns**: The EMA’s Committee for Medicinal Products for Human Use highlighted a side effect known as ARIA, which can lead to brain swelling and bleeding. The committee noted three fatalities among patients treated with Kisunla.
– **Market Position**: Despite the setback, Lilly remains hopeful about bringing Kisunla to European patients. The company has already secured approvals for the drug in the US, Japan, and the UK, and it offers a potential convenience advantage with monthly infusions compared to Leqembi, which is administered biweekly.
### Analyst Insights
William Blair analyst Myles Minter commented on the situation, stating, “We see potential for an eventual reversal of the CHMP opinion for Kisunla, but do view the probability as materially lower than that of Leqembi given the higher ARIA incidence.” He added that there is a significant risk that Kisunla may not gain approval in the EU.
### Conclusion
As Eli Lilly navigates this regulatory challenge, the future of Kisunla in the European market remains uncertain. Will the company succeed in its next review, or will it face further obstacles in bringing this Alzheimer’s treatment to patients?
**FAQ: What is the primary concern regarding Eli Lilly’s Kisunla drug?**
The primary concern is that the benefits of Kisunla do not outweigh the risks of potentially fatal brain bleeding, as highlighted by the European Medicines Agency.
